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Abstract 
Background: Insulin resistance is common in polycystic ovary syndrome (PCOS). PCOS may be 
associated with increased risk of gestational diabetes mellitus (GDM). 
Objectives: To 1) review literature regarding PCOS and hyperglycaemia in pregnancy and 2) 
present original data from Odense Child Cohort (OCC) regarding GDM in PCOS. 
Methods: Literature search including original studies from 2000-18. OCC included 2,548 pregnant 
women, 9.5 % (n=241) had PCOS. Fasting plasma glucose was measured in 1,519 and 659 oral 
glucose tolerance tests were performed (with risk factor for GDM, n= 384, without risk factors, 
n=275), applying two different GDM criteria 
Results: 30 studies were eligible using 12 different sets of diagnostic criteria for GDM. Ten studies 
included n > 50, control group, assessment of GDM and BMI. Results were not uniform, but 
supported that higher BMI, higher age, Asian ethnicity, and fertility treatment increased the risk of 
GDM in PCOS. In OCC, women with PCOS and controls had similar prevalences of GDM 
independent of different sets of criteria for GDM. 
Conclusion: PCOS may not be an individual risk factor for GDM. Pregnancies in PCOS are 
characterized by factors known to increase risk of GDM, especially high BMI and fertility 
treatment. 
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1 Introduction 
Polycystic ovary syndrome (PCOS) is a frequent endocrine disorder in females with an estimated 
prevalence of 5 - 10 % [1]. PCOS is usually defined by the Rotterdam criteria, where at least two 
out of the following criteria must be fulfilled; Clinical and/or biochemical signs of 
hyperandrogenism, polycystic ovaries and oligo- or anovulation. Additionally, other causes of the 
symptoms and findings must be ruled out [2]. Insulin resistance is observed in about 50 % of 
women with PCOS [3] and the risk of type 2 diabetes mellitus (T2D) is reportedly fourfold higher 
in non-pregnant women with PCOS than those without PCOS , with diagnosis 4 years earlier [4]. 
Insulin resistance and risk of T2D in PCOS are closely associated with obesity [5, 6] and T2D is 
rarely diagnosed in normal weight women with PCOS [5-7].    
To date there is conflicting evidence whether PCOS per se increases the risk of GDM [8, 9] or 
whether obesity is the key factor. Available studies regarding risk of GDM in PCOS are mainly 
retrospective [10-15]. Register-based data have demonstrated that the prevalence of GDM is 
significantly higher in Danish women with PCOS compared to controls (4 vs. 0.6 %, p<0.001) [4]. 
Such studies may be biased towards higher incidence of GDM in PCOS, as they potentially favor a 
more severe PCOS phenotype [4] and are subject to surveillance bias. It is estimated that 10 - 50 % 
of women with GDM develop diabetes during a 5-year interval following delivery [16, 17]. The 
prevalence of GDM in cohort studies varied widely between 2 and 32 %, depending on the women 
included, screening procedure, geographic setting and especially applied diagnostic criteria [18-20]. 
It has been shown that the use of different diagnostic criteria within the same population may 
identify women with different phenotypes [21] and indicates the necessity of uniform diagnostic 
criteria for comparison studies [21]. It is not possible to pool data from all populations, as it is well 
known that ethnicity affects both PCOS phenotype and prevalence of GDM [22-24]. There has been 
focus on increased risk of GDM in Asia [22-24], but we need more knowledge about PCOS and 
GDM from areas such as Africa. 
The Hyperglycemia and Adverse Outcome (HAPO) study reported that glucose levels during an 
oral glucose tolerance test (OGTT) in gestational weeks 24 - 28 were linearly associated with 
perinatal outcomes [25]. New diagnostic GDM criteria were proposed based on the results from the 
HAPO study [26] and these GDM criteria were endorsed by the World Health Organization (WHO) 
in 2013 [27]. However, few studies have been published regarding the impact of implementing 
these criteria in different populations. In Denmark, GDM is diagnosed by a 75 g OGTT at 
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gestational week 28, performed in women with clinical risk factors and using a diagnostic 2 h 
threshold of 9.0 mmol/l [28], resulting in a prevalence of 3 % [29]. The implementation of WHO 
GDM criteria [27] is expected to increase the number of women with GDM substantially [30].  
 
In this paper we 1) review previous studies on GDM prevalence in women with PCOS and 2) 
present new data on GDM applying two different sets of GDM criteria in a large cohort of 
unselected Danish pregnant women with prospective characterization of PCOS status. 
 
2 Narrative review 
PubMed was searched to identify studies in English published between January 2000 and March 
2018, that reported prevalence of GDM in women with PCOS. The following search string was 
used: (“PCOS” OR “polycystic ovary syndrome”) AND (“GDM” OR “gestational diabetes 
mellitus” OR “diabetes, gestational” OR “diabetes mellitus, type 2”). The inclusion criteria were 
original data regarding prevalence af GDM (prospective, retrospective, registerbased) in women 
with PCOS.  
 
836 articles were identified by the initial search. 343 review articles were excluded and additionally 
463 articles were excluded because of irrelevance. Thirty studies fullfilled inclusion criteria; 10 
prospective [31-40] and 20 retrospective studies [4, 10-15, 23, 41-52]. Included studies reported 
data on 11,263 women with PCOS and 1,389,161 controls. The median number of women with 
PCOS per study was 375 (Table 1). The origin of the studies was: 12 European [4, 11, 14, 31-33, 
35, 37, 39, 41, 44, 46, 49], 8 Asian [12, 15, 40, 42, 43, 47, 51, 52], 7 American [13, 34, 38, 45, 48] 
and 3 Australian studies [10, 36, 50]. 
Twelve different sets of diagnostic criteria for GDM were used in the 30 studies (Table S2). The 
most frequently used criteria were those of the American College of Obstetricians and 
Gynecologists (ACOG) [53] (n=7) [23, 32, 33, 39, 42, 45, 49], followed by American Diabetes 
Association (ADA2000) [54] (n=6) [13, 34, 41-43, 52], WHO1999 [55] (n=5) [33, 35, 37, 38, 51], 
WHO13/International Association of the Diabetes and Pregnancy Study Group (IADPSG) [26, 56] 
(n=3) [15, 40, 47], Danish criteria (GDM-DK) [18] (n=2) [4, 46] and the Modified IADPSG (n=2) 
[35, 37]. The following criteria were only applied in one study each: National Diabetes Data Group 
(NDDG) [57] (n=1) [12] and Australasian Diabetes in Pregnancy Society (ADIPS) [58] (n=1) [50]. 
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Four studies used their own criteria [11, 14, 31, 44], in 2 studies GDM was self-reported [10, 36] 
and one study did not define GDM criteria [48].       
The study aim was to compare the risk of hyperglycemia in pregnancy in PCOS vs. controls. 
Therefore, we defined clinically relevant criteria for inclusion of studies in a thorough analysis. The 
studies should include a control group, a substantial number of participants, arbitrarily > 50 women 
with PCOS, and assessment of both hyperglycemia and BMI during pregnancy. Furthermore, 
medical treatment with e.g. metformin during pregancy should be avoided [59]. Ethnicity affects the 
PCOS phenotype and the risk of GDM [22-24], and therefore studies were divided according to 
ethnicity of included women.   
Five out of 30 studies [23, 32, 35, 37, 39] included no control group and additional seven out of 30 
studies [31, 38, 41, 47, 49, 51, 52] included less than 50 women with PCOS. Four studies [4, 12, 14, 
45] were register-based and BMI was not reported. The prospective study by Joham et al. [36] was 
community based and the diagnosis of GDM or T2D was self-reported. Likewise, GDM was self-
reported in the retrospetive study by Kakoly et al. [10]. Women with PCOS were treated with 
metformin during pregnancy in two studies by Glueck et al. [34] and Reyes-Munoz et al. [13]. A 
total of twenty out of 30 studies [4, 10, 12-14, 23, 31, 32, 34-39, 41, 45, 47, 49, 51, 52] were 
excluded and  therefore 10 out of 30 studies [11, 15, 33, 40, 42-44, 46, 48, 50] were eligible for 
detailed evaluation. Six out of 10 studies [11, 33, 44, 46, 48, 50] were performed in primarily white 
women and 4 out of 10 papers [15, 40, 42, 43] included women of predominantly Asian origin. 
The prevalence of GDM in six studies performed in predominantly white study populations (Table 
1) varied from 4.9 to 38.5 % in women with PCOS, and from 5 to 17 % in controls. Four out of 6 
studies [11, 33, 46, 48] showed significantly higher prevalence of GDM in women with PCOS 
compared to controls. Three out of these 4 studies [11, 33] found significantly higher BMI in 
women with PCOS compared to controls (24.6 vs. 23.7 kg/m
2
, 25.6 vs. 23.0 kg/m
2
 and 24.6 vs. 23.6 
kg/m
2 
in PCOS vs. controls, p<0.02, p<0.0001 and p<0.05, respectively) and the remaining study 
[48] found no significant difference in BMI between women with PCOS and controls (25.9 vs. 23.2 
kg/m
2
 in PCOS vs. controls, p<0.23). Age at delivery, was significantly lower in two out of six 
studies [33, 48] in PCOS compared to controls (30 vs. 30.7 years and 33 vs. 35 years in PCOS vs. 
controls, respectively, p<0.01 and p<0.002). In one out of 6 studies [11] age was higher in women 
with PCOS compared to controls (30.4 vs. 29.4 years, p<0.05). Women with PCOS and controls 
had comparable age in 3 out of 6 studies [44, 46, 50] and age in controls was matched to women 
with PCOS in one paper [50]. 
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GDM prevalence in the 4 studies performed in Asian populations [15, 40, 42, 43] varied from 1.1 to 
55.7 % in women with PCOS, and from 1.8 to 29.9 % in controls. Three out of 4 studies [15, 40, 
42] showed significantly higher prevalence of GDM in women with PCOS compared to controls. 
One of these 3 studies [15] found significantly higher BMI in women with PCOS vs. controls 
(p<0.001). Two studies [40, 42] reported no significant diffence in BMI between PCOS and 
controls. However, mean BMIs were numerically higher in PCOS (BMI 23.0 vs. 20.0 kg/m
2
 and 
26.1 vs. 25.5 kg/m
2
 (p<0.3)). In one out of 4 studies, Han et al. [43] studied the risk of GDM in 
both lean and obese women and found that the prevalence of GDM was comparable in PCOS vs. 
controls (27.5 vs. 27.5 kg/m
2
 in obese and 20.5 vs. 20.6 kg/m
2
 in lean women with PCOS vs. 
controls, respectively). In all 4 studies [15, 40, 42, 43] maternal age was higher in PCOS compared 
to control women (29.7 vs. 28.6 years (p<0.001), 30.8 vs. 29.1 years, 30.5 vs. 28.9 years (p<0.002) 
and in the study by Han et al. 31.6 vs. 32.2 years in obese and 31.2 vs. 32.5 years in lean women, 
respectively p<0.001).   
 
The six studies on white women [11, 33, 44, 46, 48, 50] will be compared with the present 
prospective study, OCC.      
3 Odense Child Cohort 
Odense Child Cohort (OCC) is a prospective cohort study. Details regarding design and study 
cohort have been published recently [60].  
All pregnant women between January 2010 until December 2012 were invited to participate. PCOS 
was defined as self-reported PCOS or hirsutism alone or together with self-reported irregular 
menstrual cycle. WHO ICD10 diagnostic codes for hirsutism and PCOS were extracted from the 
Patient Register of the county of Funen (FPAS) in women without returned questionnaires. The 
study complied with the Helsinki declaration and was approved by the Regional Scientific Ethics 
Committee for Southern Denmark (project ID S-20090130). All participants gave written informed 
consent.  
A flow chart for women in OCC is presented in Figure 2 and Figure S1. A total of 2,548 women 
had information regarding PCOS/hirsutism status, 241 (9.5 %) women were categorized as PCOS 
and the remaining 2,307 women were defined as controls. Among women with known 
PCOS/hirsuitism status, 23 (1 %) women were diagnosed with GDM early in pregnancy and were 
excluded in the present paper. This left 2,525 women eligible for 3
rd
 trimester OGTT. Fasting 
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plasma glucose (FPG) was available in 1,519 (60 %) and 659 (26 %) underwent an OGTT at GA 
28-30; 384 due to risk factors and 275 by randomization. The rate of women undergoing OGTT was 
similar in PCOS vs. controls (32 vs. 25 %, p<0.1). Risk factors for GDM were defined by Danish 
guidelines for antenatal care [29]; BMI ≥ 27 kg/m2, previous GDM, previous delivery of a 
macrosomic child (birth weight ≥ 4,500 g), family history of diabetes mellitus (DM) or glucosuria 
detected during pregnancy. 
Women with risk factors for GDM were offered a diagnostic OGTT at gestational age (GA) 28-30 
weeks. For each women who was offered OGTT by indication, one random woman from the cohort 
was offered a diagnostic OGTT at GA 28 weeks matched by gestational age. Randomization of 
women without risk factors for GDM was conducted consecutively throughout the study period.  
As per protocol in the OCC study, venous samples were obtained after overnight fasting and 
additionally at 1 h and 2 h during a 75 g glucose OGTT. According to WHO13/IADPSG criteria 
[26, 56], GDM was diagnosed by FPG ≥ 5.1 mmol/l, and/or 1 h plasma glucose (PG) ≥ 10 mmol/l, 
and/or 2 h PG ≥ 8.5 mmol/l. In the Danish guidelines for antenatal care, GDM was defined by 2 h 
PG ≥ 9.0 mmol/l [29] and only these women received treatment for GDM. 
4 Statistics 
Differences between groups were analysed using t-tests for normally distributed continous 
variables, Wilcoxon’s rank sum test for non-normally distributed continous variables and the Chi2 
test for dichotomous variables. Data are presented as frequency and percentage or median and 
quartiles. The frequency of GDM was computed after application of diagnostic criteria as described 
above. A p-value < 0.05 was considered statistically significant. Statistical calculations were 
performed using Stata version 15.0 (StataCorp, Texas, USA). 
5 Results 
Baseline characteristics are shown in Table 2. Women with PCOS had significantly higher BMI 
than women without PCOS (p<0.02), but were of similar age. Women in OCC were younger than 
the Danish background population (p<0.001) and had slightly higher BMI (p<0.04). Women with 
PCOS had more pregnancies achieved by fertility treatment and fewer pregnancies achieved within 
6 months than controls. Futhermore, by definition, women with PCOS had higher prevalence of 
irregular menstrual cycle before pregnancy. 
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The prevalence of GDM applying the two sets of criteria is shown in Figure 2. The prevalence of 
GDM among women undergoing routine OGTT due on risk factors and randomly selected women 
were 7.6 and 3.3 %, respectively, using GDM-DK criteria [18]. GDM prevalence based on the 
WHO13/IADPSG [26, 56] was 64.6 and 40.0 % in women with GDM risk factors and randomly 
selected women, respectively. GDM diagnosis based on diagnostic venous plasma glucose 
thresholds at 0 h, 1 h and 2 h during OGTT are presented in Table 3.  
The characteristics of women with PCOS and controls diagnosed with GDM according to two 
different sets of criteria are shown in Table S1. Among women with GDM WHO13/IADPSG 
criteria [26], we found that fewer women were Caucasian among women with PCOS compared to 
women without PCOS (90 vs. 94 %, p<0.02). There was no difference in maternal age, BMI or 
venous plasma glucose in the fasting state or post load (1 h or 2 h) in women with PCOS vs. 
controls using either sets of criteria. 
 
6 Discussion 
6.1 GDM in women with and without PCOS 
In this narrative review on hyperglycemia during pregnancy in women with PCOS, 30 studies were 
identified between 2000-2018. Ten studies were available for detailed review as they included 
relevant information on a control group, more than 50 participants with PCOS, recorded BMI data 
and lack of medication for PCOS in pregnancy [11, 15, 33, 40, 42-44, 46, 48, 50]. Six studies 
included predominantly white women [11, 33, 44, 46, 48, 50] and four studies included women of 
Asian origin [15, 40, 42, 43]. In the Danish prospective study, OCC, we found similar prevalences 
of GDM in women with PCOS and controls, irrespective of the diagnostic criteria applied, even 
though mean BMI was significantly higher in women with PCOS vs. controls (25.3 vs. 24.2 kg/m
2
, 
p<0.05). Importantly, the inclusion and management of women during pregnancy, regarding 
indication for OGTT and applied GDM criteria were similar in women with PCOS and controls in 
OCC and PCOS status was not asssociated with additional visits or surveillance during pregnancy 
[61]. Women in OCC were predominanly white and therefore our study results were compared to 
the 6 pstudies in predominantly white women [11, 33, 44, 46, 48, 50]. These 6 papers consisted of 
one recent prospective study [33] and 5 retrospective studies [11, 44, 46, 48, 50]. Relatively few 
women with PCOS were included in four of the five retrospective studies [11, 44, 48, 50] (n=66, 
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99, 71 and 60, respectively), whereas the last retrospective study [46] included 199 women with 
PCOS. 
Two studies of white women by Haakova et al. [44] and Vollenhoven et al. [50] reported a similar 
frequency of GDM in women with PCOS compared to controls (GDM prevalences 4.9 vs. 12.2 % 
and 22 vs. 17 %, respectively, p>0.05), in accordance with OCC. Importantly, both these studies 
[44, 50] matched women with PCOS and controls acccording to age and BMI. Vollenhoven et al. 
[50] also matched women according to ethnicity.  
In contrast, 4 out of 6 studies previous studies [11, 33, 46, 48] from white populations reported 
increased risk of GDM in PCOS vs. controls. The prospective study by deWilde et al. [33] reported 
a fourfold increased prevalence of GDM in women with PCOS compared to controls (prevalence 
GDM in PCOS vs. controls 23 vs. 5 %, p<0.001). However, this study included only with PCOS 
who required fertility treatment.  Further, difference the screening protocol and criteria for GDM 
differed between PCOS women and controls and BMI was significantly higher in women with 
PCOS vs. controls (median 24.6 vs. 23.7 kg/m
2
, p<0.02). These factors could explain the increased 
risk of GDM in PCOS [33]. Mikola et al. [11] and Sterling et al. [48] found 2.2 to 3.2 fold increased 
risk of GDM in PCOS. Women with PCOS had higher BMI than controls in both studies [11, 48], 
but the increased risk for GDM in PCOS persisted after correcting for BMI. However, women with 
PCOS (28, 22) had required fertility treatment, which suggests a more severe PCOS phenotype and 
in vitro fertilization as well as assisted reproduction are associated with an increased risk of GDM 
[62]. Women with PCOS tended to be older than controls in the study by Mikola et al. [11] (30.4 vs. 
29.5 years, p=0.05), which could also have increased  GDM risk [22]. In the study by Sterling et al. 
[48] women with PCOS were significantly younger than controls (33 vs. 35 years, p<0.002). 
However, no GDM criteria were cited in this paper [48]. Finally, Mumm et al. [46] reported a 
significantly higher prevalence of GDM in women with PCOS vs. controls (38.5 vs. 13.8 %, 
p<0.05). BMI was significantly higher in PCOS compared to controls (p<0.05). PCOS women were 
recruited from the outpatient clinic and may represent more severe cases of PCOS. Mumm et al. 
[46] had no data on regional fat mass in their retrospective study, but suggested that central obesity 
could be an independent predictor of the risk of GDM in women with PCOS [46]. It has been 
reported, that body composition in women with PCOS and previous GDM is characterized by 
central fat distribution while BMI was comparable in PCOS and controls [63].  
In conclusion, OCC and two previous studies in white women with PCOS [44, 50] reported no 
increased risk of GDM in PCOS, whereas four [11, 33, 46, 48] studies reported increased 
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prevalence of GDM. The four contrary studies were heterogeneous in design and study population, 
making firm conclusions difficult. However, higher BMI, and requirement for fertility treatment 
could have resulted in hyperglycemia in pregnancy in PCOS, and especially lack of [33] or 
unreported [48] uniform GDM criteria also limits comparisons.  
 
Four of 10 studies [15, 40, 42, 43] were carried out in Asian women; one prospective [40] and 3 
retrospective studies [15, 42, 43], including one study from western Asia, Iran [42]. Three out of 4 
studies [15, 40, 42] showed significantly higher prevalence of GDM in women with PCOS 
compared to controls and one study [43] only found this association in obese women. Just one 
retrospective study [15] observed significant higher BMI in PCOS vs. controls. Two out of 4 studies 
[42, 43] included exclusively women with a history of infertility. It has been shown that Asian 
women with PCOS have an OR of 3.5 for GDM compared to white women [23]. However, use of a 
standard OGTT may be questioned in an Asian study population as Olabi et al. [24] reported height 
to be inversely associated with 2 h glucose. Therefore, populations with a lower height, i.e. Asians 
may receive a relatively higher glucose load which could lead to over-diagnosis of GDM. In the 
prospective study by Wang et al. [40] the difference in GDM prevalence between lean women with 
and without PCOS was as high as 38.5 % with an OR of 5.6 in PCOS vs. controls, however, 
average BMI in lean women were not presented. The GDM prevalence was comparable between 
obese women with PCOS and controls [40]. Two retrospective studies in Chinese study populations 
[15, 43] reported a moderately increased risk of GDM in PCOS. Both studies [15, 43] were based 
on hospital records. However, the selection of women for GDM screening was not described in the 
study by Xiao et al. [15]. The study by Han et al. [43] only included infertile women and presented 
data for lean women with PCOS vs. controls (average BMI 20.5 kg/m
2 
in
 
PCOS and 20.6 kg/m
2
 in 
controls). The prevalence of GDM was 1.1 % in PCOS and 1.8 % in controls, whereas 
corresponding prevalence of GDM in obese women was 10.5 and 8.6 %, respectively [40]. In all 4 
Asian studies [15, 40, 42, 43] women with PCOS were significantly older than controls, which 
might partly explain increased GDM prevalence, as previously described [22].      
In conclusion, 3 out of the 4 Asian studies [15, 40, 42] showed significantly higher GDM 
prevalence in women with PCOS compared to controls in lean populations. The last study [43] 
found only increased GDM prevalence in obese women with PCOS. This study included only 
infertile women [43]. BMI in 3 of the 4 Asian studies [40, 42, 43] was comparable in women with 
PCOS vs. controls, but age was significantly higher in women with PCOS in all 4 studies [15, 40, 
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42, 43]. These findings may suggest that BMI in Asian women is not as important for the risk of 
GDM in women with PCOS compared to the white populations, however, older age predicatably  
increased the risk of GDM. These data were in accordance with previous papers [22-24].  
 
The present review and results from OCC corroborate findings from a meta-analysis concluding 
that higher risk of GDM in women with PCOS was a questionable finding because of significant 
heterogeneity between available studies [8]. However, a recent meta-analysis including 40 studies 
showed an increased risk of GDM in women with PCOS with a RR of 2.78, but substantial 
heterogeneity was observed (p<0.001) and subgroup analysis suggested that different study designs 
and pre-pregnancy BMI might affect these associations [9].  
Overall, we consider that past and current data do not support an increased risk of GDM in women 
with PCOS per se. However, many characteristics in PCOS may elevate risk of hyperglycemia in 
pregnancy, such as higher BMI, age and fertility treatment. Ethnicity also needs to be considered. 
Last but not least, in general, the criteria used for diagnosing GDM when comparing PCOS to 
controls need to be uniformly applied. 
6.2 GDM rates for different diagnostic criteria 
Depending on diagnostic thresholds for fasting and postload glucose levels, different phenotypes 
may be identified as having GDM [21]. An overview of different GDM criteria is given in Table 
S2. The 30 included studies in Table 1 used 12 different sets of diagnostic criteria for GDM. Two 
out of 30 studies [10, 36] used self-reported GDM based on questionnaires. Fasting and 2 h glucose 
thresholds values varied from 4.8 to 7.0 mmol/l and 8.0 to 12.2 mmol/l, respectively. In a post-hoc 
analysis on 273 pregnant women with PCOS, Helseth et al. [35] applied both WHO13/IADPSG and 
WHO1999 GDM criteria on their study cohort of women with PCOS and reported a GDM 
prevalence of 24.2 and 25.6 %, respectively. Even though GDM rates were similar, less than one-
third of women with GDM by one of the two sets of criteria fulfilled both criteria. Furthermore, the 
two groups had different profiles for clinical risk factors and thus different in phenotypic 
characteristics. The study included no control group. In another Norwegian study (n=759), Jenum et 
al. [64] found WHO13/IADPSG GDM rates of 13.0 % and WHO1999 rates of 31.5 %. These 
findings indicate that using different GDM criteria might have different impacts in different groups 
(e.g. PCOS vs. the general population). When testing for GDM in early pregnancy (n=228), 
Odsaeter et al. found a GDM prevalence of 15.5 and 24.1 % by WHO13/IADPSG criteria 
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(modified as 1 h glucose values were not available) and WHO1999 criteria, respectively. Recently, 
it has been questioned whether WHO13/IADPSG criteria can be used in early pregnancy, and the 
IADPSG is no longer recommending this [65]. 
The HAPO study with 23,957 participants in 15 different centers, found a prevalence of GDM using 
the WHO13/IADPSG criteria of 17.8 % (9.3 - 25.5 %), with FPG as the diagnostic value in 55 % 
[66]. The studies in Table 1 with the most substantial increase in GDM prevalence in women with 
PCOS compared to control, was mainly using the ACOG, ADA [13, 41] and IADPSG [40, 47] 
criteria with a low FPG thresholds of 5.3 and 5.1 mmol/l, respectively. In addition, one study used 
local criteria [11] with an even lower FPG at 4.8 mmol/l. Thus, the choice of GDM definition 
potentially has a major influence on the findings of an association between PCOS and GDM. 
In OCC, women with clinical risk factors had a 64.6 % risk for GDM by WHO13/IADPSG criteria 
compared to a 40.0 % risk in women without risk factors. Corresponding figures for GDM-DK 
criteria were 7.6 and 3.3 %. Thus, applying WHO13/IADPSG criteria, substantially increased the 
incidence of GDM compared to the GDM-DK criteria in both women with and without PCOS. The 
WHO13/IADPSG criteria have been endorsed by the Danish Society of Obstetrics and 
Gynaecology (DSOG) but implementation is awaiting more data in the Danish population and 
estimates of health economics [28].      
Among the women who underwent OGTT, we found that FPG, 1 h PG and 2 h PG alone identified 
42, 13 and 11 % GDM cases, respectively. Figures were similar in women with and without PCOS 
(Table 3). This is in accordance with the HAPO study where the majority of women with GDM 
were identified by FPG [66]. 
6.3 Strengths and limitations in OCC 
The main strengths of OCC are the prospective study design with thorough and homogeneous data 
collection in all women with or without PCOS. The inclusion and management of women during 
pregnancy, regarding indication for OGTT and applied GDM criteria were similar in women with 
and without PCOS. Futhermore, women with GDM in early pregnancy were excluded. Women in 
OCC with PCOS did not have more visits or focus dependent on PCOS status [61]. A limitation 
was the use of self-reported data on hirsutism, family history of diabetes mellitus, as well as PCOS 
diagnosis. Nevertheless, the prevalence in this cohort reflected previous estimates in PCOS [67] and 
self-reported PCOS has been reported to correspond well to the clinical diagnosis [36, 68]. 
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Furthermore, the PCOS diagnosis was validated by extraction of the PCOS diagnosis from the 
Patient Register.  
7 Conclusion 
This review revealed that the risk of GDM in white women with PCOS and controls was dependent 
on the women’s BMI, use of fertility treatment, as well as various GDM criteria. Ethnicity affects 
the rate of PCOS and GDM. Among Asian women with PCOS and controls, the risk of GDM was 
dependent of the women’s age and use of fertility treatment.      
In the prospective cohort, OCC, the rate of GDM was comparable in women with PCOS compared 
to controls despite higher BMI in PCOS, suggesting that PCOS per se did not predispose to 
hyperglycemia in pregnancy. Application of the WHO13/IADPSG criteria for GDM in Danish 
women with risk factors for GDM would increase the number of GDM cases in the OCC nearly 
tenfold [41]. 
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Legends to figures 
 
Figure 1.  
Flowchart, narrative review. 
 
Figure 2. 
Flowchart OCC.  
GDM risk divided by OGTT by risk factor and randomization. 
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Figure 2. 
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Fasting glucose at GA 28-30 (n=1,519) 
 
OGTT at GA 28-30 
(n=659) 
De to kasse 
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Legends to tables 
 
Table 1.  
Characteristics of studies included in the review.  
Data are presented as mean or numbers (percent). NA=not applicable.  
#median, $non-insulin resistant, *Compared to controls. 
 
Table 2.  
Baseline characteristics of 237 women with PCOS and 2,288 controls after exclusion of 23 
women with early GDM. 
Data are extracted from medical records and presented as number (percent), median (quartiles) and 
mean (± SD). Data marked with 
#
 were based on returned questionnaires (n = 174 women with 
PCOS and n = 1,361 controls). BMI: Body mass index, DM: diabetes mellitus. 
*p<0.05 (PCOS vs. controls). 
**p<0.05 (OCC vs. Danish background population). 
‡Characteristics in 389,609 Danish women (after exclusion of 2.2% (n=9,014) with GDM) giving 
birth to a singleton from 2004 to 2010 (mean (± SD)).  
Background data are given as mean (± SD) and percent as in the reference. 
¤Available. 
 
Table 3.  
Diagnostic criteria for GDM in the fasting state and during OGTT in women with PCOS vs. 
controls.  
Data are presented as numbers (percent). 
 
Table S1.  
Maternal characteristics and OGTT results for women with PCOS and controls, according to 
two different sets of criteria for GDM.  
Data are presented as median (25
th
-75
th
 percentile) or numbers (percent). WHO2013/IADPSG: 
Fasting venous plasma glucose ≥ 5.1 mmol/l and/or ≥ 10.0 mmol/l at 1 h and/or ≥ 8.5 mmol/l at 2 h. 
GDM-DKplasma: 2 h venous plasma glucose ≥ 9.0 mmol/l. 
P-value < 0.05 in bold, when comparing characteristics by PCOS status, Wilcoxon’s rank sum test 
(non-normally distributed variables) and Chi squared test for categorical variables.  
 
Table S2.  
Diagnostic threshold values for different GDM criteria. 
FPG, fasting plasma glucose; OGTT, oral glucose tolerance test; NDDG, National Diabetes Data 
group; ACOG, American College of Obstetricians and Gynecologists; ADA, American Diabetes 
Association; WHO, World Health Organization; IADPSG, International Association of Diabetes in 
Pregnancy Study Group; Mod. IADPSG, modified IADPSG; GDM-DK, Danish national criteria; 
ADIPS, Australasian Diabetes in Pregnancy Society. 
  
Table 1.  
 
25.0-29.9 > 30.0 25.0-29.9 > 30.0
WHO13/IADPSG 53 54 No
GDM-DK 5 6 No
Lo et al. [23] 2017 California Retrospective Rotterdam ACOG NA 988 NA 32.9 NA 25.5 55.3 19.8 NA
Rubin et al. [4] 2017 Denmark Retrospective ICD-10 GDM-DK 28-30 1,162 54,680 25 35 4 0.6 Yes
deWilde et al. [33] 2017 The Netherlands Prospective Rotterdam ACOG/WHO 24-26 188 2,889 30.0# 30.7# 24.6# 23.7# 100 Risk factors 23 5 Yes
Kakoly et al. [10] 2017 Australia Retrospective Selfreported Selfreported NA 662 7,326 36.6 36.8 29.2 26.2 14.1 7.4 Yes
Xiao et al. [15] 2016 China Retrospective Rotterdam IADPSG 24-28 352 2,037 27.7 28.6 12.3 1.5 5.0 0.6 100 100 18 14 Yes
deWilde et al. [32] 2015 The Netherlands Prospective Rotterdam ACOG 24-26 72 NA 29.6# NA 24.4# 100 n/a 31 NA
WHO 24.1
Mod.IADPSG 15.5
Pan et al. [12] 2015 Taiwan Retrospective ICD-9 NDDG 24-28 3,109 31,090 29.1 29.1 100 100 20 11 Yes
Sawada et al. [47] 2015 Japan Retrospective Japanese criteria IADPSG NA 49 49 31.7 31.9 24.4 24.2 100 100 24.5 10.2 Yes
Sterling et al. [48] 2015 Canada Retrospective Rotterdam NA NA 71 323 33# 35# 24.6 23.6 15.5 5 Yes
Joham et al. [36] 2014 Australia Prospective Selfreported Selfreported NA 478 8,134 30.5 30.6 28.0 25.1 25.7 32.2 22.4 15.1 11 4 Yes
Mumm et al. [46] 2014 Denmark Retrospective Rotterdam GDM-DK 28-30 157 995 29# 29# 25.9# 23.2# 20 12 38.5 13.8 Yes
Ashrafi et al. [42] 2014 Iran Retrospective Rotterdam ADA/ACOG 24-28 234 234 29.6 30.7 26.1 25.5 44.4 29.9 Yes
Wan et al. [51] 2014 Hong Kong Retrospective Rotterdam WHO NA 24 171 31.4 32.7 22.8 21.5 29.2 30.4 No
WHO 25.6
Mod. IADPSG 24.2
Wang et al. [40] 2013 China Prospective Rotterdam IADPSG 24-28 115 592 30.8 29.1 23.0 20.0 100 100 55.7 17.2 Yes
Reyes-Munoz et al. [13] 2012 Mexico Retrospective Rotterdam ADA 14-24 and 24-28 52 52 29.1 29.0 27.5 27.5 57.6 23 57.6 23 100 100 26.9 9.6 Yes
Roos et al. [14] 2011 Sweden Retrospective ICD-9/ICD-10 Own criteria NA 379 1,191,336 NA NA NA 28.5 32.1 24.5 10.3 3 1 Yes
31.6 32.2 27.5 27.5 10.5 8.6
31.2 32.5 20.5 20.6 1.1 1.8
Veltmann-Verhulst et al. [39] 2010 The Netherlands Prospective Rotterdam ACOG 24-26 50 NA 100 n/a 42 NA
Altieri et al. [41] 2010 Italy Retrospective Selfreported ADA NA 15 159 34.7 32.6 24.3 23.0 20 4 Yes
Sir-Petermann et al. [38] 2007 Chile Prospective NIH/Rotterdam WHO 10-16 and 22-28 48 51 29.0# 26.0# 28.6# 24.2# 100 100 12.2 2 Yes
Lo et al. [45] 2006 California Retrospective ICD-9 ACOG NA 1,542 84,882 31.4 29.7 95 95 14.3 5.9 Yes
Glueck et al. [34] 2004 USA Prospective Rotterdam ADA 26-28 90 252 33 29 33.8 25.6 9.5 15.9 No
Weerakiet et al. [52] 2004 Thailand Retrospective Rotterdam ADA 24-28 47 264 31.6 31.3 24.0 22.1 76.6 37.9 22.2 18 No
Turhan et al. [49] 2003 Turkey Retrospective Rotterdam ACOG 24-28 38 136 27.6 26.6 31.5 23.6 100 100 2.6 8.1 No
Haakova et al. [44] 2003 Czech Republic Retrospective Rotterdam Own criteria
second and third 
trimester 66 66 29 29.8 23.7 23.2 100 100 4.92 12.2 No
Bjercke et al. [31] 2002 Norway Prospective Rotterdam Own criteria NA 29$ 355 31.5 32.7 25.2 21.9 7 0.6 Yes
Mikola et al. [11] 2001 Finland Retrospective Rotterdam Own criteria second trimester 99 737 30.4 29.4 25.6 23.0 32 35 20 9 Yes
Vollenhoven et al. [50] 2000 Australia Retrospective Rotterdam ADIPS 26-28 60 60 27.1 26.5 100 100 22 17 No
Prevalence GDM (%)
NA 19.3 NA NA
NA
NA
NA NA
NA
NA NA
NA NA
60.3 20.3 19.4 66.9 22.9 10.2 32
NA
NA NA
42.2 62.6
NA NA NA
NA NA
Increased 
risk of 
GDM in 
PCOS controls
PCOS controls< 24.9
NA n/a
NA NA
NA
NA n/a
NA NA
NA NA
NA
19.2
NA NA NA
NA
25
BMI, mean BMI (%) OGTT performed (%)
Study (reference) Published Nationality Study design PCOS diagnosis GDM criteria
GA at OGTT 
(weeks) PCOS controls< 24.9PCOS controls PCOS controls PCOS controls
n Age, mean
NA 40
237 2,288 30.6 30.2 25.3 24.2
Odsæter et al. [37] 2015 Norway Prospective Rotterdam first trimester 
Palm et al. 2018 Denmark Prospective
Selfreported and 
ICD-10 28-30
NA
NA 86.2 94.4
NA NA NA
NA NA 100 n/a NA NA
NA
NA NA
228 NA 30# NA 27.3# NA
NA NA
Helseth et al. [35] 2013 Norway Prospective Rotterdam 32 273 NA 100 n/a NA NA
NA NA
29.4 n/a 29.0 NA NA NA
19.2
NA 39.4 65.2 NA
Han et al. [43] 2011 Korea Retrospective Rotterdam
NA NA NA
60 40 81.8 18.9 NA
ADA 24 336 1,003 NA NA
NA NA NA
NA
63.8 36.2 85.2 14.8
No
NA NA NA
NA
NA
n/a 53 n/a 24
 
 
  
 27 
 
 
Table 2.  
 
Total PCOS Controls Danish background 
population¤ n = 2,525 n = 237 n = 2,288 
Age, years  30 (27-33)  30 (28-33)  30 (27-33)  - 
Age, years, mean (± SD)** 30.2 (± 4.5) 30.6 (± 4.4) 30.2 (± 4.5) 30.7 (± 4.8) 
Primiparity  1400 (56)  126 (53)  1274 (56)  44.1  
BMI, kg/m
2
* 23.3 (21.2-26.4)  23.8 (21.5-28.0)  23.3 (21.2-26.2)  - 
BMI, kg/m
2
, mean (± SD)** 24.3 (± 4.7) 25.3 (± 5.5) 24.2 (± 4.6) 24.1 (± 4.8) 
Caucasian# 2,292 (91)  209 (89)  2,083 (91)  -  
Family history of DM#* 194 (10)  34 (17)  160 (10)  -  
Age at menarche, years#* 13 (12-14)  13 (12-14)  13 (12-14)  -  
Previous oral contraceptive pill treatment# 1251 (92)  133 (91)  1,118 (92)  -  
Pregnancy achieved by fertility treatment#* 166 (12)  49 (36)  117 (10)  -  
Pregnancy achieved within 6 months# 643 (48)  51 (36)  592 (50)  -  
Previous pregnancy# 843 (56)  95 (61)  748 (56)  -  
Previous miscarriage#* 284 (34)  41 (43)  243 (32)  -  
Smoking before pregnancy# 361 (27)  35 (24)  326 (28)  -  
Smoking during 1
st 
trimester#  54 (7)  5 (5)  49 (7)  12.6  
Regular menstrual cycle before pregnancy#* 1208 (91)  86 (71)  1,122 (93)  -  
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Table 3.  
 
 Total  PCOS Controls 
WHO/IADPSG criteria 
Fasting plasma glucose ≥ 5.1 mmol/l 635/1,519 (42) 68/148 (46) 567/1,371 (41) 
(n=1,519)    
1-hour plasma glucose ≥ 10.0 mmol/l 82/621 (13) 11/75 (15) 71/546 (13) 
(n=621)    
2-hour plasma glucose ≥ 8.5 mmol/l 66/624 (11) 5/75 (7) 61/549 (11) 
(n=624)    
 
 
 
 
 
 
 
